


Psoriatic Arthritis Treatment Market Focuses On Effective Treatment Response With The Development Of Novel Drugs

The Business Research Company's Psoriatic Arthritis Treatment Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, March 9, 2022 /EINPresswire.com/ -- The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the [global psoriatic arthritis treatment market](#). Janus kinase (JAK) inhibitors are orally administered small molecules emerging as a novel

treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases – tofacitinib, baricitinib, and upadacitinib. Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In June 2020, AbbVie, a leading US-based pharmaceutical company has announced that it has applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor with the U.S. Food and Drug Administration and the European Medicines Agency.

The global psoriatic arthritis treatment market size is expected to grow from \$7.89 billion in 2021 to \$8.92 billion in 2022 at a compound annual growth rate (CAGR) of 13.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global psoriatic arthritis treatment market share is expected to reach \$13.17 billion in 2026 at a CAGR of 10.2%.



Psoriatic Arthritis Treatment Global Market Report 2022-Market Size, Trends, And Global Forecast 2022-2026

Read more on the Global Psoriatic Arthritis Treatment Market Report:

<https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report>

The rise in the prevalence of psoriasis & psoriatic arthritis disease boosted the growth of the psoriatic arthritis treatment market. Psoriasis (Pso) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30% in psoriatic patients. According to the national psoriasis foundation, more than 8 million Americans have psoriasis. According to the National Psoriasis Foundation, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis. According to the psoriatic arthritis treatment market research, an increase in the prevalence of psoriasis & psoriatic arthritis disease drives market growth.

Major players covered in the global psoriatic arthritis treatment industry are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly And Company, Pfizer, UCB Biosciences Inc and Hoffmann La Roche Ltd.

TBRC's global psoriatic arthritis treatment market report is segmented by drug class into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, others, by route of administration into oral, parenteral, topical, by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

[Psoriatic Arthritis Treatment Global Market Report 2022](#) – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologics), By Route Of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a psoriatic arthritis treatment market overview, forecast psoriatic arthritis treatment market size and growth for the whole market, psoriatic arthritis treatment market segments, geographies, psoriatic arthritis treatment market trends, psoriatic arthritis treatment market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Psoriatic Arthritis Treatment Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Arthritis Monoclonal Antibodies Global Market Report 2022 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia), By End-Use (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report>

Psoriasis Global Market Report 2021 - By Drug class (Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor), By Distribution Channel (Hospitals, Retail Pharmacies, E-Commerce), By Drug Types (Small molecules, Biologics), By Route Of Administration (Oral, Topical, Injectable), By Disease Indication (Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis), COVID-19 Impact And Recovery
<https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report>

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
<https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report>

About The Business Research Company

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/565067662>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.